{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:35:59Z","timestamp":1791336959076,"version":"4.3.1"},"reference-count":86,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000691","name":"Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000770","name":"University of Manchester","doi-asserted-by":"publisher","award":["CS2041"],"award-info":[{"award-number":["CS2041"]}],"id":[{"id":"10.13039\/501100000770","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007730","name":"American Medical Systems","doi-asserted-by":"publisher","award":["SBF006\\u22161165"],"award-info":[{"award-number":["SBF006\\u22161165"]}],"id":[{"id":"10.13039\/100007730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UKRI","doi-asserted-by":"publisher","award":["MR\/X03383X\/1"],"award-info":[{"award-number":["MR\/X03383X\/1"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.medj.2025.100987","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T15:54:12Z","timestamp":1770393252000},"page":"100987","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Lymphocyte alterations and elevated complement signaling are key features of refractory myasthenia gravis"],"prefix":"10.1016","volume":"7","author":[{"given":"Katherine C.","family":"Dodd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Baillie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James K.L.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Isabel","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.L.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Spillane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Viegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wioleta M.","family":"Zelek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Sussman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2516-9438","authenticated-orcid":false,"given":"Madhvi","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2025.100987_bib1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/mus.26114","article-title":"Burden of illness in patients with treatment refractory myasthenia gravis","volume":"58","author":"Engel-Nitz","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.medj.2025.100987_bib2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/13696998.2019.1592180","article-title":"Healthcare resource utilization by patients with treatment-refractory myasthenia gravis in England","volume":"22","author":"Harris","year":"2019","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.medj.2025.100987_bib3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"10.1016\/j.medj.2025.100987_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ensci.2024.100541","article-title":"Myasthenia gravis: The evolving therapeutic landscape","volume":"37","author":"Wolfe","year":"2024","journal-title":"eNeurologicalSci"},{"key":"10.1016\/j.medj.2025.100987_bib5","article-title":"Exploring the clinical significance of anti-acetylcholine receptor antibody titers, changes, and change rates in Myasthenia Gravis","volume":"15","author":"Luo","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.medj.2025.100987_bib6","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/jnnp-2020-325511","article-title":"Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome","volume":"92","author":"Kojima","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.medj.2025.100987_bib7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13019-024-02511-6","article-title":"Thymoma negatively affects the neurological outcome of myasthenia gravis after thymectomy: a propensity score matching study","volume":"19","author":"Tian","year":"2024","journal-title":"J. Cardiothorac. Surg."},{"key":"10.1016\/j.medj.2025.100987_bib8","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/s12883-023-03406-0","article-title":"Female sex and overweight are associated with a lower quality of life in patients with myasthenia gravis: a single center cohort study","volume":"23","author":"Wilcke","year":"2023","journal-title":"BMC Neurol."},{"key":"10.1016\/j.medj.2025.100987_bib9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1084\/jem.184.2.349","article-title":"Both CD4 and CD8 T cells are essential to induce experimental autoimmune myasthenia gravis","volume":"184","author":"Zhang","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.medj.2025.100987_bib10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.clim.2012.09.012","article-title":"Impaired regulatory function in circulating CD4 CD25highCD127low\/\u2212 T cells in patients with myasthenia gravis","volume":"145","author":"Thiruppathi","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.medj.2025.100987_bib11","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-11-3900","article-title":"Functional defect of regulatory CD4+ CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis","volume":"105","author":"Balandina","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.medj.2025.100987_bib12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jneuroim.2013.09.006","article-title":"Disturbed B cell subpopulations and increased plasma cells in myasthenia gravis patients","volume":"264","author":"Kohler","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.medj.2025.100987_bib13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/08916934.2018.1454913","article-title":"Altered expression of transcription factors IRF4 and IRF8 in peripheral blood B cells is associated with clinical severity and circulating plasma cells frequency in patients with myasthenia gravis","volume":"51","author":"Zhang","year":"2018","journal-title":"Autoimmunity"},{"key":"10.1016\/j.medj.2025.100987_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109184","article-title":"Single-cell mapping reveals dysregulation of immune cell populations and VISTA+ monocytes in myasthenia gravis","volume":"245","author":"Fan","year":"2022","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.medj.2025.100987_bib15","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1177\/0300060513505267","article-title":"Mycophenolate mofetil improves neurological function and alters blood T-lymphocyte subsets in rats with experimental autoimmune encephalomyelitis","volume":"42","author":"Zhu","year":"2014","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.medj.2025.100987_bib16","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1212\/WNL.35.10.1455","article-title":"Use of monoclonal antiacetylcholine receptor antibodies to investigate the macrophage inflammation of acute experimental myasthenia gravis: refractoriness to a second episode of acute disease","volume":"35","author":"Corey","year":"1985","journal-title":"Neurology"},{"key":"10.1016\/j.medj.2025.100987_bib17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/mus.20794","article-title":"Antigen-specific T-cell activation in hyperplastic thymus in myasthenia gravis","volume":"36","author":"Utsugisawa","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.medj.2025.100987_bib18","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/mus.10362","article-title":"Dendritic cells in hyperplastic thymuses from patients with myasthenia gravis","volume":"27","author":"Nagane","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.medj.2025.100987_bib19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000529626","article-title":"Aberrant dendritic cell subsets in patients with myasthenia gravis and related clinical features","volume":"30","author":"Song","year":"2023","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.medj.2025.100987_bib20","article-title":"Causal relationship between the immune phenotype of monocytes and myasthenia gravis: A Mendelian randomization study","volume":"10","author":"Dong","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.medj.2025.100987_bib21","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1212\/WNL.43.6.1167","article-title":"Myasthenia gravis: Quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients","volume":"43","author":"Nakano","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.medj.2025.100987_bib22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jneuroim.2004.08.002","article-title":"The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo","volume":"158","author":"Romi","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.medj.2025.100987_bib23","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/mus.21398","article-title":"Correlation of C3 level with severity of generalized myasthenia gravis","volume":"40","author":"Liu","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.medj.2025.100987_bib24","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3390\/biomedicines10061360","article-title":"Complement activation profile in myasthenia gravis patients: Perspectives for tailoring anti-complement therapy","volume":"10","author":"Iacomino","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.medj.2025.100987_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420935697","article-title":"C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis","volume":"13","author":"Aguirre","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.medj.2025.100987_bib26","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.4049\/jimmunol.171.7.3847","article-title":"Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis","volume":"171","author":"T\u00fcz\u00fcn","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.medj.2025.100987_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0065-2776(08)60908-6","article-title":"The role of complement in B cell activation and tolerance","volume":"74","author":"Carroll","year":"2000","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.medj.2025.100987_bib28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"Dunkelberger","year":"2010","journal-title":"Cell Res."},{"key":"10.1016\/j.medj.2025.100987_bib29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jneuroim.2012.11.003","article-title":"The increased expression of CD21 on AchR specified B cells in patients with myasthenia gravis","volume":"256","author":"Yin","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.medj.2025.100987_bib30","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.3389\/fimmu.2019.01493","article-title":"Complement Receptor Type 1 (CR1, CD35), the Inhibitor of BCR-Mediated Human B Cell Activation, Differentially Regulates TLR7, and TLR9 Induced Responses","volume":"10","author":"M\u00e1csik-Valent","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2025.100987_bib31","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5758192","article-title":"Complement Receptor Type 1 Suppresses Human B Cell Functions in SLE Patients","volume":"2016","author":"Kremlitzka","year":"2016","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.medj.2025.100987_bib32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2012.01.003","article-title":"DAF\/CD55 and Protectin\/CD59 modulate adaptive immunity and disease outcome in experimental autoimmune myasthenia gravis","volume":"244","author":"Soltys","year":"2012","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.medj.2025.100987_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/mus.23448","article-title":"Cell surface complement regulators moderate experimental myasthenia gravis pathology","volume":"47","author":"Kusner","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.medj.2025.100987_bib34","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.4049\/jimmunol.177.2.1070","article-title":"Costimulation via CD55 on human CD4+ T cells mediated by CD97","volume":"177","author":"Capasso","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.medj.2025.100987_bib35","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.it.2005.12.008","article-title":"Holding T cells in check--a new role for complement regulators?","volume":"27","author":"Longhi","year":"2006","journal-title":"Trends Immunol."},{"key":"10.1016\/j.medj.2025.100987_bib36","unstructured":"England, N.H.S. (2018). Clinical Commissioning Policy Statement: Rituximab bio-similar for the treatment of myasthenia gravis (adults)."},{"key":"10.1016\/j.medj.2025.100987_bib37","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1136\/ard-2024-225587","article-title":"Defects in B-lymphopoiesis and B-cell maturation underlie prolonged B-cell depletion in ANCA-associated vasculitis","volume":"83","author":"Thiel","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.medj.2025.100987_bib38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jneuroim.2012.12.001","article-title":"Expansion of circulating counterparts of follicular helper T cells in patients with myasthenia gravis","volume":"256","author":"Luo","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.medj.2025.100987_bib39","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000945","article-title":"Immune Skew of Circulating Follicular Helper T Cells Associates With Myasthenia Gravis Severity","volume":"8","author":"Ashida","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.medj.2025.100987_bib40","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.medj.2025.100987_bib41","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jamaneurol.2014.4103","article-title":"A genome-wide association study of myasthenia gravis","volume":"72","author":"Renton","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.medj.2025.100987_bib42","article-title":"CTLA4 variants and haplotype contribute genetic susceptibility to myasthenia gravis in northern Chinese population","volume":"9","author":"Sun","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.medj.2025.100987_bib43","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2796.2007.01879.x","article-title":"Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravis","volume":"263","author":"Wang","year":"2007","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.medj.2025.100987_bib44","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2025.100987_bib45","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1007\/s00415-022-11197-6","article-title":"Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression","volume":"269","author":"Dorcet","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.medj.2025.100987_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.106130","article-title":"Comparison of peripheral blood B cell subset ratios and B cell-related cytokine levels between ocular and generalized myasthenia gravis","volume":"80","author":"Hu","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.medj.2025.100987_bib47","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jneuroim.2008.06.027","article-title":"The myasthenia gravis thymus: a rare source of human autoantibody-secreting plasma cells for testing potential therapeutics","volume":"201","author":"Hill","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.medj.2025.100987_bib48","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL-6 in inflammation, autoimmunity and cancer","volume":"33","author":"Hirano","year":"2021","journal-title":"Int. Immunol."},{"key":"10.1016\/j.medj.2025.100987_bib49","first-page":"2668","article-title":"Regulatory T cells and B cells: implication on autoimmune diseases","volume":"6","author":"Wang","year":"2013","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.medj.2025.100987_bib50","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jneuroim.2019.05.004","article-title":"Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis","volume":"332","author":"Jing","year":"2019","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.medj.2025.100987_bib51","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1474-4422(24)00514-3","article-title":"Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"24","author":"Habib","year":"2025","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.medj.2025.100987_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2015.07.011","article-title":"Regulatory dendritic cells in autoimmunity: A comprehensive review","volume":"63","author":"Liu","year":"2015","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.medj.2025.100987_bib53","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.4049\/jimmunol.177.8.5296","article-title":"Suppression of experimental autoimmune myasthenia gravis by granulocyte-macrophage colony-stimulating factor is associated with an expansion of FoxP3+ regulatory T cells","volume":"177","author":"Sheng","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.medj.2025.100987_bib54","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/j.1468-1331.2012.03773.x","article-title":"Vitamin D deficiency in patients with myasthenia gravis and improvement of fatigue after supplementation of vitamin D3: a pilot study","volume":"19","author":"Askmark","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.medj.2025.100987_bib55","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-017-0892-8","article-title":"Regulatory T cells in multiple sclerosis and myasthenia gravis","volume":"14","author":"Danikowski","year":"2017","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.medj.2025.100987_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2019.01107","article-title":"Adoptive transfer of regulatory T cells as a promising immunotherapy for the treatment of multiple sclerosis","volume":"13","author":"Duffy","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.medj.2025.100987_bib57","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1365-2567.2012.03572.x","article-title":"Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers","volume":"136","author":"Himmel","year":"2012","journal-title":"Immunology"},{"key":"10.1016\/j.medj.2025.100987_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.864403","article-title":"Nanoparticles for Inducing Antigen-Specific T Cell Tolerance in Autoimmune Diseases","volume":"13","author":"Benne","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2025.100987_bib59","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fimmu.2013.00245","article-title":"Treg inducing adjuvants for therapeutic vaccination against chronic inflammatory diseases","volume":"4","author":"Keijzer","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2025.100987_bib60","article-title":"Peptide-MHC-Based Nanomedicines for the Treatment of Autoimmunity: Engineering, Mechanisms, and Diseases","volume":"11","author":"Serra","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2025.100987_bib61","article-title":"A new platform for autoimmune diseases. Inducing tolerance with liposomes encapsulating autoantigens","volume":"48","author":"Almenara-Fuentes","year":"2023","journal-title":"Nanomedicine"},{"key":"10.1016\/j.medj.2025.100987_bib63","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.3390\/pharmaceutics13111949","article-title":"Retinoic acid-containing liposomes for the induction of antigen-specific regulatory T cells as a treatment for autoimmune diseases","volume":"13","author":"Ter Braake","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.medj.2025.100987_bib64","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.4049\/jimmunol.144.5.1711","article-title":"Use of synthetic peptides to establish anti-human acetylcholine receptor CD4+ cell lines from myasthenia gravis patients","volume":"144","author":"Protti","year":"1990","journal-title":"J. Immunol."},{"key":"10.1016\/j.medj.2025.100987_bib65","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/s41423-024-01167-5","article-title":"The role of plasmacytoid dendritic cells (pDCs) in immunity during viral infections and beyond","volume":"21","author":"Ngo","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.medj.2025.100987_bib66","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.clim.2018.10.012","article-title":"Imbalance of the two main circulating dendritic cell subsets in patients with myasthenia gravis","volume":"205","author":"Chen","year":"2019","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.medj.2025.100987_bib67","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1136\/jnnp.56.1.46","article-title":"Thymectomy and azathioprine have no effect on the phenotype of CD4 T lymphocyte subsets in myasthenia gravis","volume":"56","author":"Melms","year":"1993","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.medj.2025.100987_bib68","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1189\/jlb.0706481","article-title":"Critical role of monocytes to support normal B cell and diffuse large B cell lymphoma survival and proliferation","volume":"82","author":"Mueller","year":"2007","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.medj.2025.100987_bib69","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.4049\/jimmunol.172.5.2778","article-title":"CD86 and CD80 differentially modulate the suppressive function of human regulatory T cells","volume":"172","author":"Zheng","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.medj.2025.100987_bib70","doi-asserted-by":"crossref","first-page":"179","DOI":"10.20517\/2347-8659.2017.29","article-title":"Peripheral NK and B regulatory cell frequencies are altered with symptomatic exacerbation in generalized myasthenia gravis patients","volume":"4","author":"Lai","year":"2017","journal-title":"Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.medj.2025.100987_bib71","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4049\/jimmunol.2300015","article-title":"A Noncanonical CD56dimCD16dim\/- NK Cell Subset Indicative of Prior Cytotoxic Activity Is Elevated in Patients with Autoantibody-Mediated Neurologic Diseases","volume":"212","author":"Yandamuri","year":"2024","journal-title":"J. Immunol."},{"key":"10.1016\/j.medj.2025.100987_bib72","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001169","article-title":"Heterogeneity of acetylcholine receptor autoantibody\u2013mediated complement activity in patients with myasthenia gravis","volume":"9","author":"Obaid","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.medj.2025.100987_bib73","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/intimm\/dxs090","article-title":"Complement receptor type 1 (CR1, CD35) is a potent inhibitor of B-cell functions in rheumatoid arthritis patients","volume":"25","author":"Kremlitzka","year":"2013","journal-title":"Int. Immunol."},{"key":"10.1016\/j.medj.2025.100987_bib74","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1084\/jem.20040863","article-title":"The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo","volume":"201","author":"Liu","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.medj.2025.100987_bib75","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.4049\/jimmunol.179.5.3178","article-title":"Complement-dependent enhancement of CD8+ T cell immunity to lymphocytic choriomeningitis virus infection in decay-accelerating factor-deficient mice","volume":"179","author":"Fang","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.medj.2025.100987_bib76","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/eji.200324259","article-title":"CD46-mediated costimulation induces a Th1-biased response and enhances early TCR\/CD3 signaling in human CD4+ T lymphocytes","volume":"34","author":"S\u00e1nchez","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.medj.2025.100987_bib77","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/ni.1917","article-title":"Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells","volume":"11","author":"Cardone","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2025.100987_bib78","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.imlet.2018.06.003","article-title":"CD46 is a potent co-stimulatory receptor for expansion of human IFN-\u03b3-producing CD8 + T cells","volume":"200","author":"Hansen","year":"2018","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.medj.2025.100987_bib79","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1172\/JCI29251","article-title":"Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis","volume":"116","author":"Astier","year":"2006","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.medj.2025.100987_bib80","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis","volume":"77","author":"Brauner","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.medj.2025.100987_bib81","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMoa2501561","article-title":"A phase 3 trial of inebilizumab in generalized myasthenia gravis","volume":"392","author":"Nowak","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100987_bib82","author":"Chang"},{"key":"10.1016\/j.medj.2025.100987_bib84","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/cei.12472","article-title":"Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura","volume":"179","author":"Becerra","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.medj.2025.100987_bib85","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/ene.14500","article-title":"Changes in serum complements and their regulators in generalized myasthenia gravis","volume":"28","author":"Ozawa","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.medj.2025.100987_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.968206","article-title":"Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients","volume":"13","author":"Lekova","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2025.100987_bib87","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/mus.27973","article-title":"Activation of the classical complement pathway in myasthenia gravis with acetylcholine receptor antibodies","volume":"68","author":"Ozawa","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.medj.2025.100987_bib88","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3181\/00379727-105-26050","article-title":"Changes in Serum Complement Activity in Patients with Myasthenia Gravis","volume":"105","author":"Nastuk","year":"1960","journal-title":"Proc. Soc. Exp. Biol. Med."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025004143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025004143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:36:35Z","timestamp":1773419795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634025004143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2666634025004143"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2025.100987","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphocyte alterations and elevated complement signaling are key features of refractory myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2025.100987","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100987"}}